Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Public ClinicalTrials.gov record NCT04713592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects With Moderate to Severe Plaque Psoriasis With Palmoplantar (Non-Pustular) Involvement (PPPsO)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Palmoplantar (non-pustular) plaque psoriasis (PPPsO) represents a localized form of psoriasis in palms and soles. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis with palmoplantar involvement and to assess change in disease symptoms. Risankizumab is an approved drug for the treatment of psoriasis. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo in Period A. In Period B, all the participants will receive risankizumab. Around 168 adult participants with a moderate to severe plaque psoriasis will be enrolled in approximately 55 sites across the world. Participants will receive single subcutaneous (administered under the skin) risankizumab or placebo in period A (16 weeks). In period B (36 weeks), all participants will receive subcutaneous risankizumab once every 12 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT04713592
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 174 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2021
- Primary completion
- Apr 19, 2023
- Completion
- Apr 19, 2023
- Last update posted
- Jun 13, 2024
2021 – 2023
United States locations
- U.S. sites
- 34
- U.S. states
- 22
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Research Associates - Glendale /ID# 219197 | Glendale | Arizona | 85308 | — |
| Burke Pharmaceutical Research /ID# 223349 | Hot Springs | Arkansas | 71913-6404 | — |
| NW Arkansas Clinical Trials Center /ID# 231602 | Rogers | Arkansas | 72758 | — |
| Dermatology Research Associates /ID# 219195 | Los Angeles | California | 90045 | — |
| Integrative Skin Science and Research /ID# 219216 | Sacramento | California | 95815 | — |
| Medderm Associates /ID# 219210 | San Diego | California | 92103 | — |
| Colorado Center for Dermatology, PLLC /ID# 219223 | Centennial | Colorado | 80111-1724 | — |
| Skin Care Research - Hollywood /ID# 219184 | Hollywood | Florida | 33021-6748 | — |
| GSI Clinical Research, LLC /ID# 219175 | Margate | Florida | 33063 | — |
| Savin Medical Group, LLC /ID# 227754 | Miami Lakes | Florida | 33014-2490 | — |
| Lenus Research & Medical Group /ID# 219202 | Sweetwater | Florida | 33172 | — |
| Hamilton Research, LLC /ID# 219224 | Alpharetta | Georgia | 30022 | — |
| Arlington Dermatology /ID# 219211 | Rolling Meadows | Illinois | 60008 | — |
| Northshore University Health System Dermatology Clinical Trials Unit /ID# 219220 | Skokie | Illinois | 60077 | — |
| Dawes Fretzin, LLC /ID# 219219 | Indianapolis | Indiana | 46256 | — |
| The Dermatology Center PSC - New Albany /ID# 219183 | New Albany | Indiana | 47150 | — |
| Epiphany Dermatology of Kansas LLC /ID# 219208 | Overland Park | Kansas | 66210 | — |
| Allcutis Research LLC /ID# 222272 | Methuen | Massachusetts | 01844-5864 | — |
| David Fivenson, MD, PLC /ID# 219180 | Ann Arbor | Michigan | 48103 | — |
| Henry Ford Medical Center /ID# 219205 | Detroit | Michigan | 48202-3046 | — |
| Advanced Dermatology of the Midlands /ID# 219207 | Omaha | Nebraska | 68144-1105 | — |
| Psoriasis Treatment Center of Central New Jersey /ID# 219201 | East Windsor | New Jersey | 08520 | — |
| Forest Hills Dermatology Group /ID# 219200 | Kew Gardens | New York | 11415 | — |
| Icahn School of Medicine at Mount Sinai /ID# 219206 | New York | New York | 10029-6504 | — |
| ClinOhio Research Services /ID# 222298 | Columbus | Ohio | 43213-4440 | — |
| University of Pittsburgh MC /ID# 219203 | Pittsburgh | Pennsylvania | 15260 | — |
| Velocity Clinical Research-Providence /ID# 223350 | East Greenwich | Rhode Island | 02818 | — |
| Palmetto Clinical Trial Services /ID# 222275 | Fountain Inn | South Carolina | 29644-1928 | — |
| Palmetto Clinical Trial Services /ID# 222299 | Fountain Inn | South Carolina | 29644-1928 | — |
| International Clinical Research - Tennessee LLC /ID# 220930 | Murfreesboro | Tennessee | 37130-2450 | — |
| Menter Dermatology Res Inst /ID# 219161 | Dallas | Texas | 75246 | — |
| Center for Clinical Studies - Houston (Binz) /ID# 219221 | Houston | Texas | 77004-8097 | — |
| Advanced Clinical Research - Woseth Dermatology /ID# 224750 | Salt Lake City | Utah | 84117-4209 | — |
| Virginia Clinical Research, Inc. /ID# 219181 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04713592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2024 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04713592 live on ClinicalTrials.gov.